Andy Studna, Editor

As studies become more complex, stakeholders must be aware of the resources they are utilizing and their impact on the environment.

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, highlights how sites are bearing the burdens of cost and training with implementing new technologies.

A number of topics including DE&I, collaboration, and decentralized trials have been front and center at the clinical research industry’s largest meetings.

In this video interview, Jimmy Bechtel, vice president, site engagement, SCRS, discusses challenges and trends he is currently hearing about from sites.

While recent advancements in technology are helping studies operate more efficiently, concerns around their accuracy and usability still remain.

Industry experts share their perspectives on the potential of AI in clinical trials.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, highlights the need for relevant, quality data and the challenges with needing to use multiple technologies.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, discusses how sponsors can ensure that patients are properly reporting data.

Industry leaders share their perspectives on the guidance and how it will affect sponsors moving forward.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, touches on the usability of clinical technology.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, highlights challenges with patient data from an operational perspective.

In this video interview with ACT editor Andy, Studna, Silvio Galea, chief data & analytics officer, WCG, discusses the lack of awareness surrounding clinical research.

In a fireside chat with ACT editor Andy Studna, Bowdish, from a clinical research cancer center, shares her experience with these relationships and how to streamline clinical operations.

Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, discusses how the guidance should prompt better-designed oncology trials and greater diversity.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, touches on challenges that may be created by the guidance such as meeting multiple regulatory requirements.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, discusses how sponsors will need to plan ahead even further for their oncology trials.

Arexvy, recently approved for adults 50 through 59 years of age at increased risk, succeeds in trial of adults aged 60 and older through multiple respiratory syncytial virus seasons.

In this video interview with ACT editor Andy Studna, Mwango Kashoki, SVP, global head of regulatory strategy, Parexel, highlights how FDA’s multiregional clinical trials in oncology guidance encourages more diverse site locations and patient populations.

In this video interview with ACT editor Andy Studna, Kashoki, SVP, global head of regulatory strategy, discusses the new draft guidance and its emphasis on proactive planning.

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara looks forward and shares her insights on the future of data management.

Emergex’s T cell-priming candidate will be studied in early-phase trials in search for next generation of COVID-19 vaccines.

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara discusses how improper data collection can extend timelines and incur additional cost.

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara touches on the burden associated with data collection.

The study will evaluate the safety and efficacy of a casdatifan plus volrustomig combination for the treatment of clear cell renal cell carcinoma.

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara discusses the lack of submission standards for clinical data.

Findings from two Baltimore medical centers presented at the American Society for Radiation Oncology Annual Meeting suggest spiritual themes and distrust may be behind the decline in trial participation.

In this video interview with ACT editor Andy Studna, Erin Erginer, director of product, Certara highlights challenges with data volume and complexity.

In this video interview with ACT editor Andy Studna, Rich Gliklich, founder of OM1 highlights personalized medicine and predicting disease outcomes.

Recent study compared patient enrollment trends in industry- and federally sponsored oncology trials.